Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesDividends payablesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

cbdMD (YCBD) Total Liabilities (2016 - 2025)

Historic Total Liabilities for cbdMD (YCBD) over the last 10 years, with Q4 2025 value amounting to $2.8 million.

  • cbdMD's Total Liabilities fell 7158.03% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.8 million, marking a year-over-year decrease of 7158.03%. This contributed to the annual value of $3.2 million for FY2025, which is 6294.0% down from last year.
  • Latest data reveals that cbdMD reported Total Liabilities of $2.8 million as of Q4 2025, which was down 7158.03% from $3.2 million recorded in Q3 2025.
  • Over the past 5 years, cbdMD's Total Liabilities peaked at $35.2 million during Q1 2021, and registered a low of $2.8 million during Q4 2025.
  • For the 5-year period, cbdMD's Total Liabilities averaged around $11.6 million, with its median value being $9.6 million (2022).
  • Per our database at Business Quant, cbdMD's Total Liabilities soared by 7220.12% in 2021 and then tumbled by 7158.03% in 2025.
  • Over the past 5 years, cbdMD's Total Liabilities (Quarter) stood at $14.9 million in 2021, then crashed by 38.79% to $9.1 million in 2022, then decreased by 11.8% to $8.1 million in 2023, then increased by 21.13% to $9.8 million in 2024, then tumbled by 71.58% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q4 2025, $3.2 million for Q3 2025, and $3.8 million during Q2 2025.